The EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy.
CGI PLC is creating a portfolio of cannabis and hemp-related Intellectual Property assets that meet clear commercial needs which offer our shareholders best-in-class returns. CGI’s long term strategy is to be the global leader in the production of medical, recreational cannabinoid extracts, oils, nutraceuticals, and pharmaceuticals with a solid set of highly developed IP assets. These assets will be licensed to companies capable of delivering our revolutionary cannabis based products to the global market place.